ClinicalTrials.gg
Drug

Toripalimab clinical trials

Also written JS001, Tuoyi, Loqtorzi and TAB001.

studies test it
362
open now
178
in phase 3
41
first study started
2016

How each study uses toripalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the toripalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Oct 2023 · LOQTORZI · BLA 761240 (FDA, Drugs@FDA)
European Union
19 Sept 2024 · Loqtorzi · EMEA/H/C/006120 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Toripalimab
198
Toripalimab Injection
18
anti-PD-1 monoclonal antibody
6
TORIPALIMAB INJECTION(JS001 )
5
JS001, TAB001
5

Brand

Tuoyi
8
Loqtorzi
7

Development codes

JS001
59
TAB001
5
CHS-007
2
HX-008
2

Other names

Tripleitriumab
1

In one entry with another drug

Given together, or one or the other

axitinib plus toripalimab
3
CM082 plus JS001
3
Toripalimab combined with Lenvatinib
2
Toripalimab combined with Bevacizumab
2
Toripalimab and Anlotinib
2
Disitamab Vedotin and Toripalimab
2
RC48-ADC and JS001
2
Toripalimab plus Lenvatinib
2

Studies by the year they started

361 studies that test it; most in 2020 (58); 1 more planned to start later

Studies that test toripalimab, by start year
YearStudies
20162
20173
20189
201947
202058
202148
202237
202340
202440
202536
202641

Who runs them

Industry 31 · Other 331

Sun Yat-sen University (52) · Shanghai Junshi Bioscience Co., Ltd. (33) · Fudan University (17) · Tianjin Medical University Cancer Institute and Hospital (12) · Peking University Cancer Hospital & Institute (11) · Peking University (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Peking Union Medical College Hospital (8)

Often tested with

Tested in the same studies.

Anlotinib (18) · Lenvatinib (12) · Surufatinib (11) · Cisplatin (9) · Paclitaxel (9) · Disitamab vedotin (9) · Gemcitabine (7) · Axitinib (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Toripalimab is the comparator. A study of two new drugs counts under both.

  • 1Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Shanghai Junshi Bioscience Co., Ltd. · next primary completion Oct 2029
  • 1JS007 · Shanghai Junshi Bioscience Co., Ltd. · next primary completion Oct 2029
  • 1Anlotinib · The First Affiliated Hospital of Zhengzhou University · next primary completion Dec 2028
  • 1Benmelstobart · The First Affiliated Hospital of Zhengzhou University · next primary completion Dec 2028
  • 1Nimotuzumab · Sun Yat-sen University · next primary completion Jul 2030
  • 1Gemcitabine · Zhiquan Hu · next primary completion Jul 2028
  • 1Trastuzumab rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Mar 2028
  • 1Adebrelimab · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Mar 2028
Reaching primary completion within a year · 41, 9 in phase 3

Studies that test toripalimab, phase 3 first.

Studies

Open first, then newest update. How each study uses toripalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 362

See all 362 studies that test toripalimab →

Given beside what is tested · 134 — toripalimab is usual care or a partner of the new treatment

Showing 20 of 134.

As the comparator · 8 — what is tested is compared with toripalimab

Codes

What other systems call toripalimab · ClinicalTrials.gg INT001244

  • MeSH (NLM) C000656314toripalimabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 8JXN261VVATORIPALIMABConfirmed FDA, NLM
  • NCI Thesaurus C131334ToripalimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.